These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38982397)
1. Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study. Weinstein DA; Jackson RJ; Brennan EA; Williams M; Davison JE; Boer F; Derks T; Ellerton C; Faragher B; Gribben J; Labrune P; McKittrick KM; Murphy E; Ross KM; Steuerwald U; Voillot C; Woodward A; Mundy HR Orphanet J Rare Dis; 2024 Jul; 19(1):258. PubMed ID: 38982397 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I. Ross KM; Brown LM; Corrado MM; Chengsupanimit T; Curry LM; Ferrecchia IA; Porras LY; Mathew JT; Weinstein DA JIMD Rep; 2016; 26():85-90. PubMed ID: 26303612 [TBL] [Abstract][Full Text] [Related]
3. Impact of hematopoietic stem cell transplantation in glycogen storage disease type Ib: A single-subject research design using Turki A; Stockler S; Sirrs S; Duddy K; Ho G; Elango R Mol Genet Metab Rep; 2023 Mar; 34():100955. PubMed ID: 36632325 [TBL] [Abstract][Full Text] [Related]
4. Development of minimally invasive Turki A; Stockler S; Sirrs S; Salvarinova R; Ho G; Branov J; Rosen-Heath A; Bosdet T; Elango R Mol Genet Metab Rep; 2022 Jun; 31():100880. PubMed ID: 35585965 [TBL] [Abstract][Full Text] [Related]
5. A triple-blinded crossover study to evaluate the short-term safety of sweet manioc starch for the treatment of glycogen storage disease type Ia. Monteiro VCL; de Oliveira BM; Dos Santos BB; Sperb-Ludwig F; Refosco LF; Nalin T; Derks TGJ; Moura de Souza CF; Schwartz IVD Orphanet J Rare Dis; 2021 Jun; 16(1):254. PubMed ID: 34082801 [TBL] [Abstract][Full Text] [Related]
6. Sleep and quality of life of patients with glycogen storage disease on standard and modified uncooked cornstarch. Rousseau-Nepton I; Huot C; Laforte D; Mok E; Fenyves D; Constantin E; Mitchell J Mol Genet Metab; 2018 Mar; 123(3):326-330. PubMed ID: 29223626 [TBL] [Abstract][Full Text] [Related]
7. A novel starch for the treatment of glycogen storage diseases. Bhattacharya K; Orton RC; Qi X; Mundy H; Morley DW; Champion MP; Eaton S; Tester RF; Lee PJ J Inherit Metab Dis; 2007 Jun; 30(3):350-7. PubMed ID: 17514432 [TBL] [Abstract][Full Text] [Related]
8. A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study. Bhattacharya K; Mundy H; Lilburn MF; Champion MP; Morley DW; Maillot F Orphanet J Rare Dis; 2015 Feb; 10():18. PubMed ID: 25758258 [TBL] [Abstract][Full Text] [Related]
10. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Correia CE; Bhattacharya K; Lee PJ; Shuster JJ; Theriaque DW; Shankar MN; Smit GP; Weinstein DA Am J Clin Nutr; 2008 Nov; 88(5):1272-6. PubMed ID: 18996862 [TBL] [Abstract][Full Text] [Related]
11. Use of waxy maize heat modified starch in the treatment of children between 2 and 5 years with glycogen storage disease type I: A retrospective study. Hijazi G; Pai N; Nagy LL; Herd S; Dickson J; Ram M; Inbar-Feigenberg M Mol Genet Metab Rep; 2019 Dec; 21():100536. PubMed ID: 31844626 [TBL] [Abstract][Full Text] [Related]
12. In vitro digestion of starches in a dynamic gastrointestinal model: an innovative study to optimize dietary management of patients with hepatic glycogen storage diseases. Nalin T; Venema K; Weinstein DA; de Souza CF; Perry ID; van Wandelen MT; van Rijn M; Smit GP; Schwartz IV; Derks TG J Inherit Metab Dis; 2015 May; 38(3):529-36. PubMed ID: 25224825 [TBL] [Abstract][Full Text] [Related]
13. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Roscher A; Patel J; Hewson S; Nagy L; Feigenbaum A; Kronick J; Raiman J; Schulze A; Siriwardena K; Mercimek-Mahmutoglu S Mol Genet Metab; 2014 Nov; 113(3):171-6. PubMed ID: 25266922 [TBL] [Abstract][Full Text] [Related]
14. The effect of tailoring of cornstarch intake on stature in children with glycogen storage disease type III. El-Karaksy H; El-Raziky MS; Anwar G; Mogahed E J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):195-200. PubMed ID: 25153581 [TBL] [Abstract][Full Text] [Related]
15. Utilization of cornstarch in glycogen storage disease type Ia. Bodamer OA; Feillet F; Lane RE; Lee PJ; Dixon MA; Halliday D; Leonard JV Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1251-6. PubMed ID: 12439121 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of cornstarch therapy in type III glycogen-storage disease. Gremse DA; Bucuvalas JC; Balistreri WF Am J Clin Nutr; 1990 Oct; 52(4):671-4. PubMed ID: 2403059 [TBL] [Abstract][Full Text] [Related]
17. Glycogen storage disease type I and III and pyruvate carboxylase deficiency: results of long-term treatment with uncooked cornstarch. Ullrich K; Schmidt H; van Teeffelen-Heithoff A Acta Paediatr Scand; 1988 Jul; 77(4):531-6. PubMed ID: 3134793 [TBL] [Abstract][Full Text] [Related]
18. Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective review. Dahlberg KR; Ferrecchia IA; Dambska-Williams M; Resler TE; Ross KM; Butler GL; Kuo CL; Ryan PT; Weinstein DA J Inherit Metab Dis; 2020 Mar; 43(2):269-278. PubMed ID: 31415093 [TBL] [Abstract][Full Text] [Related]
19. Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies. Ross KM; Ferrecchia IA; Dahlberg KR; Dambska M; Ryan PT; Weinstein DA Adv Nutr; 2020 Mar; 11(2):439-446. PubMed ID: 31665208 [TBL] [Abstract][Full Text] [Related]